Panacea Biotec files Regulation 10(6) disclosure for Dr Rajesh Jain's share acquisition

What Panacea Biotec announced

On 17 June 2026, Panacea Biotec Ltd filed a disclosure with the Bombay Stock Exchange (BSE) under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing states that Dr Rajesh Jain has acquired shares in the company. Apart from confirming the existence of the acquisition, the filing does not provide the number of shares, the percentage of holding, or the monetary value of the transaction.

Regulation 10(6) disclosure details

Regulation 10(6) mandates that any person who acquires shares crossing the 1 % threshold (or any subsequent 1 % increment) must disclose the acquisition to the stock exchange within a stipulated time frame. The purpose is to ensure transparency for investors and to monitor potential changes in control. The filing submitted by Panacea Biotec complies with this requirement, but the company chose not to disclose the quantitative details, which is permissible when the information is not deemed material beyond the regulatory threshold.

Key facts at a glance

Why this matters for investors

The disclosure confirms that a significant shareholder, Dr Rajesh Jain, has increased his stake in Panacea Biotec. While the exact size of the holding is not disclosed, the requirement to file under Regulation 10(6) indicates that the acquisition crossed at least the 1 % threshold. Investors should note that such disclosures can signal a change in the shareholding pattern, which may affect voting dynamics and future strategic decisions. However, without quantitative details, the material impact on the company’s capital structure cannot be quantified at this stage.

Conclusion

Panacea Biotec has complied with SEBI’s SAST regulations by filing a Regulation 10(6) disclosure for Dr Rajesh Jain’s share acquisition on 17 June 2026. The filing confirms the acquisition but does not reveal the number of shares or the transaction value. Investors will have to await any subsequent disclosures or shareholder filings for a clearer picture of the changed ownership structure.